Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Aug 19, 2023 12:59pm
179 Views
Post# 35596324

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:IF there is no PR tomorrow

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:IF there is no PR tomorrow The valuation represent exasperation from some shareholders. This management is always short of what they promised. The last real positive news for Thera was the approval of Trogarzo, at least it was positive on paper. Since this news that propelled the stock price, it is down and down and down. Sales of Trogarzo never came close to minimal expectations, then we got all this NASH smokescreen, first for HIV patients, then for general population, small phase III, big phase III, then phase II/III. All that failed because our big pharma CEO was never able to convince ant partner. Then you have the TH1902 phase I blunder, with an ill concieved protocol that lasted three times what they said it would. In parallel, Tanguay believed his own BS and borrowed money on the back of Trogarzo's approval instead of doing a financing at a ggod price. Then Levesque came in with this debt problem, but nonetheless hired staff as if he was still working at Pfizer. And now the company is in bad financial position with Marathon holding them, and they failed their latest promises on restarting TH1902's trial. So yes, some decided that this company can no longer be trusted. That does not mean that the situation is lost and selling was the right idea, but it is understandable because they are unable to deliver on simple timelines.


SPCEO1 wrote: I suspect a PR really would not change the situation as we clearly have a large seller who is selling without regard to price - they just need to get out for some reason or just can't emotionally deal with holding the stock any longer. Also, the share price is only frustrating shreholders but THTX's business is likely unaffected by it. According to Bloomberg, which admittedly cannot be fully trusted, June and July sales were pretty good.

The silence on restart of the TH-1902 trial is odd. So, one can reasonably conclude something might be up on that front, If it was material bad info, they would have to announce that. so that does not seem to be the case. It is likely just slow hospitals getting what needs to be done to start the trial actually done. On the positive side, as Palin mentioned, perhaps there is a partner that wants to change the trial before signing a partnership deal. But we really can only speculate and the simplest explanation is unfinished paperwork at the testing centers or really caerful patient selection.

The valuation is pretty crazy at the moment, but with this seller in the market, it could even go lower if they still have more to sell. 
Lee430 wrote: Sure looks like we're going under a dollar again on Monday ish... How about a PR saying something like restarted trial is moving forward a little slower than anticipated to ensure we enroll the best candidates for a successful trial.... Come on guys this is a Canadian wildfire that is burning down your business.




<< Previous
Bullboard Posts
Next >>